

NEW JERSEY Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	9,255,800	9,461,600	9,636,600	9,802,400
Prediabetes	2,603,700	2,749,300	2,884,000	2,937,500
Diagnosed diabetes	749,400	907,400	1,039,000	1,141,200
Undiagnosed diabetes	277,200	318,800	346,300	360,400
Total with diabetes (diagnosed and undiagnosed)	1,026,600	1,226,200	1,385,400	1,501,600
Complications:				
Visual impairment	122,900	144,500	160,500	171,200
Renal failure	1,790	2,090	2,310	2,440
Leg amputations	1,550	1,720	1,820	1,840
Annual deaths attributable to diabetes	8,070	9,330	10,140	10,550
Total annual cost (2015 dollars)	\$12.2 B	\$14.4 B	\$16.3 B	\$17.7 B
Annual medical costs	\$8.7 B	\$10.3 B	\$11.6 B	\$12.5 B
Annual nonmedical costs	\$3.5 B	\$4.1 B	\$4.7 B	\$5.2 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	1,385,200	1,552,500	1,762,500	1,959,500
Prediabetes	706,400	791,800	898,900	999,400
Diagnosed diabetes	261,800	293,400	333,100	370,300
Undiagnosed diabetes	97,000	108,700	123,400	137,200
Total with diabetes (diagnosed and undiagnosed)	358,800	402,100	456,500	507,500
Complications:				
Visual impairment	49,000	53,500	59,200	64,100
Renal failure	810	870	960	1,030
Leg amputations	600	630	660	680
Annual deaths attributable to diabetes	5,570	6,250	6,590	6,650
Total annual cost (2015 dollars)	\$4.6 B	\$5.1 B	\$5.8 B	\$6.5 B
Annual medical costs	\$4.3 B	\$4.8 B	\$5.5 B	\$6.1 B
Annual nonmedical costs	\$0.3 B	\$0.3 B	\$0.3 B	\$0.4 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.